Telmisartan achieved statistically superior left ventricular mass regression compared to carvedilol in hypertensive patients (15.7% vs 9.1% reduction by 3-DE; P<=0.001).
RCT (n=82)
randomized
Yes
Does telmisartan improve left ventricular mass regression compared to carvedilol in patients with mild-to-moderate hypertension?
Telmisartan provides superior left ventricular mass regression compared to carvedilol in hypertensive patients despite similar blood pressure reductions, suggesting a BP-independent mechanism.
Absolute Event Rate: 15.7% vs 9.1%
p-value: p=<=0.001
BACKGROUND: The hypothesis that left ventricular hypertrophy regression in hypertension relates to blood pressure (BP) control and to non-antihypertensive activity of some drugs was tested by comparing the effects of telmisartan and carvedilol on 24-h mean ambulatory BP and left ventricular mass (LVM) regression, measured using three-dimensional echocardiography (3-DECHO) and magnetic resonance imaging (MRI). METHODS: A total of 82 patients with mild-to-moderate hypertension and an optimal echocardiographic acoustic window were randomized to receive once-daily telmisartan 80 mg or carvedilol 25 mg for 44 weeks. RESULTS: Ten patients withdrew from the study because office diastolic BP remained >90 mm Hg. The 24-h mean ambulatory systolic/diastolic BP reductions were similar in both treatment groups (telmisartan, from 159.6 +/- 10.2/97.8 +/- 5.4 to 128.6 +/- 6.5/78.2 +/- 5.8 mm Hg; carvedilol, from 157.8 +/- 11.1/95.7 +/- 11.9 to 128.2 +/- 5.6/78.7 +/- 5.2 mm Hg). However, night-time and last 6-h mean BP reductions were nonsignificantly greater with telmisartan. Using 3-DE, telmisartan (P< .001) and carvedilol (P< .001) progressively reduced LVM index by 21.97 +/- 5.84 (15.7%) and 12.31 +/- 3.14 (9.1%) g/m2, respectively, at week 44. Similar magnitudes of reductions were observed using MRI (15.5% and 9.6%, respectively). Reductions in LVM index achieved with telmisartan were statistically superior to carvedilol (P< or = .001). CONCLUSIONS: The superior LVM regression with telmisartan versus carvedilol suggests telmisartan has a mechanism that may be beyond that of lowering BP in hypertensive patients.
Galzerano et al. (Thu,) conducted a rct in mild-to-moderate hypertension (n=82). telmisartan vs. carvedilol 25 mg was evaluated on left ventricular mass (LVM) regression (p=<=0.001). Telmisartan achieved statistically superior left ventricular mass regression compared to carvedilol in hypertensive patients (15.7% vs 9.1% reduction by 3-DE; P<=0.001).